vs
NEOGEN CORP（NEOG）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是Rocket Lab Corp的1.3倍（$224.7M vs $179.7M），NEOGEN CORP净利率更高（-7.1% vs -29.5%，领先22.4%），Rocket Lab Corp同比增速更快（35.7% vs -2.8%），NEOGEN CORP自由现金流更多（$7.8M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs -0.9%）
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
NEOG vs RKLB — 直观对比
营收规模更大
NEOG
是对方的1.3倍
$179.7M
营收增速更快
RKLB
高出38.5%
-2.8%
净利率更高
NEOG
高出22.4%
-29.5%
自由现金流更多
NEOG
多$122.0M
$-114.2M
两年增速更快
RKLB
近两年复合增速
-0.9%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $224.7M | $179.7M |
| 净利润 | $-15.9M | $-52.9M |
| 毛利率 | 47.5% | 38.0% |
| 营业利润率 | -2.4% | -28.4% |
| 净利率 | -7.1% | -29.5% |
| 营收同比 | -2.8% | 35.7% |
| 净利润同比 | 96.5% | -1.1% |
| 每股收益（稀释后） | $-0.07 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOGRKLB
| Q4 25 | $224.7M | $179.7M | ||
| Q3 25 | $209.2M | $155.1M | ||
| Q2 25 | $225.4M | $144.5M | ||
| Q1 25 | $221.0M | $122.6M | ||
| Q4 24 | $231.3M | $132.4M | ||
| Q3 24 | $217.0M | $104.8M | ||
| Q2 24 | $236.8M | $106.3M | ||
| Q1 24 | $228.8M | $92.8M |
净利润NEOGRKLB
| Q4 25 | $-15.9M | $-52.9M | ||
| Q3 25 | $36.3M | $-18.3M | ||
| Q2 25 | $-612.3M | $-66.4M | ||
| Q1 25 | $-10.9M | $-60.6M | ||
| Q4 24 | $-456.3M | $-52.3M | ||
| Q3 24 | $-12.6M | $-51.9M | ||
| Q2 24 | $-5.4M | $-41.6M | ||
| Q1 24 | $-2.0M | $-44.3M |
毛利率NEOGRKLB
| Q4 25 | 47.5% | 38.0% | ||
| Q3 25 | 45.4% | 37.0% | ||
| Q2 25 | 41.2% | 32.1% | ||
| Q1 25 | 49.9% | 28.8% | ||
| Q4 24 | 49.0% | 27.8% | ||
| Q3 24 | 48.4% | 26.7% | ||
| Q2 24 | 47.9% | 25.6% | ||
| Q1 24 | 51.1% | 26.1% |
营业利润率NEOGRKLB
| Q4 25 | -2.4% | -28.4% | ||
| Q3 25 | -7.7% | -38.0% | ||
| Q2 25 | -271.1% | -41.3% | ||
| Q1 25 | 2.4% | -48.3% | ||
| Q4 24 | -197.8% | -38.9% | ||
| Q3 24 | 1.0% | -49.5% | ||
| Q2 24 | 5.5% | -40.7% | ||
| Q1 24 | 5.3% | -46.4% |
净利率NEOGRKLB
| Q4 25 | -7.1% | -29.5% | ||
| Q3 25 | 17.4% | -11.8% | ||
| Q2 25 | -271.6% | -46.0% | ||
| Q1 25 | -4.9% | -49.5% | ||
| Q4 24 | -197.3% | -39.5% | ||
| Q3 24 | -5.8% | -49.6% | ||
| Q2 24 | -2.3% | -39.2% | ||
| Q1 24 | -0.9% | -47.7% |
每股收益（稀释后）NEOGRKLB
| Q4 25 | $-0.07 | $-0.09 | ||
| Q3 25 | $0.17 | $-0.03 | ||
| Q2 25 | $-2.82 | $-0.13 | ||
| Q1 25 | $-0.05 | $-0.12 | ||
| Q4 24 | $-2.10 | $-0.11 | ||
| Q3 24 | $-0.06 | $-0.10 | ||
| Q2 24 | $-0.02 | $-0.08 | ||
| Q1 24 | $-0.01 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.3M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $2.1B | $1.7B |
| 总资产 | $3.4B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资NEOGRKLB
| Q4 25 | $145.3M | $1.0B | ||
| Q3 25 | $138.9M | $976.7M | ||
| Q2 25 | $129.0M | $688.1M | ||
| Q1 25 | $127.7M | $428.4M | ||
| Q4 24 | $140.2M | $419.0M | ||
| Q3 24 | $120.5M | $442.4M | ||
| Q2 24 | $170.9M | $496.8M | ||
| Q1 24 | $168.4M | $492.5M |
总债务NEOGRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益NEOGRKLB
| Q4 25 | $2.1B | $1.7B | ||
| Q3 25 | $2.1B | $1.3B | ||
| Q2 25 | $2.1B | $688.5M | ||
| Q1 25 | $2.7B | $431.3M | ||
| Q4 24 | $2.7B | $382.5M | ||
| Q3 24 | $3.1B | $419.8M | ||
| Q2 24 | $3.1B | $455.2M | ||
| Q1 24 | $3.1B | $478.9M |
总资产NEOGRKLB
| Q4 25 | $3.4B | $2.3B | ||
| Q3 25 | $3.4B | $2.2B | ||
| Q2 25 | $3.4B | $1.6B | ||
| Q1 25 | $4.0B | $1.3B | ||
| Q4 24 | $4.1B | $1.2B | ||
| Q3 24 | $4.5B | $1.2B | ||
| Q2 24 | $4.5B | $1.2B | ||
| Q1 24 | $4.6B | $1.2B |
负债/权益比NEOGRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $7.8M | $-114.2M |
| 自由现金流率自由现金流/营收 | 3.5% | -63.6% |
| 资本支出强度资本支出/营收 | 5.2% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流NEOGRKLB
| Q4 25 | $19.4M | $-64.5M | ||
| Q3 25 | $10.9M | $-23.5M | ||
| Q2 25 | $16.4M | $-23.2M | ||
| Q1 25 | $19.5M | $-54.2M | ||
| Q4 24 | $40.3M | $-2.4M | ||
| Q3 24 | $-17.9M | $-30.9M | ||
| Q2 24 | $26.7M | $-13.0M | ||
| Q1 24 | $-30.2M | $-2.6M |
自由现金流NEOGRKLB
| Q4 25 | $7.8M | $-114.2M | ||
| Q3 25 | $-13.1M | $-69.4M | ||
| Q2 25 | $349.0K | $-55.3M | ||
| Q1 25 | $-13.4M | $-82.9M | ||
| Q4 24 | $23.1M | $-23.9M | ||
| Q3 24 | $-56.3M | $-41.9M | ||
| Q2 24 | $2.5M | $-28.3M | ||
| Q1 24 | $-62.3M | $-21.8M |
自由现金流率NEOGRKLB
| Q4 25 | 3.5% | -63.6% | ||
| Q3 25 | -6.3% | -44.8% | ||
| Q2 25 | 0.2% | -38.3% | ||
| Q1 25 | -6.1% | -67.6% | ||
| Q4 24 | 10.0% | -18.1% | ||
| Q3 24 | -26.0% | -40.0% | ||
| Q2 24 | 1.1% | -26.7% | ||
| Q1 24 | -27.2% | -23.5% |
资本支出强度NEOGRKLB
| Q4 25 | 5.2% | 27.6% | ||
| Q3 25 | 11.5% | 29.6% | ||
| Q2 25 | 7.1% | 22.2% | ||
| Q1 25 | 14.9% | 23.4% | ||
| Q4 24 | 7.4% | 16.3% | ||
| Q3 24 | 17.7% | 10.5% | ||
| Q2 24 | 10.2% | 14.4% | ||
| Q1 24 | 14.0% | 20.7% |
现金转化率NEOGRKLB
| Q4 25 | — | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
